Pharmaceuticals · 6 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The review finds that PLGA-based drug delivery systems can improve drug bioavailability and reduce adverse effects, but low drug-loading capacity, high production costs, and insufficient clinical trial data remain major barriers to clinical translation.
The review covers PLGA's physicochemical properties, synthesis processes, degradation mechanisms, and biomedical applications including drug delivery for tumor, neurodegenerative, pulmonary, bone, ocular, cardiovascular, and inflammatory diseases, as well as immunomodulation, diagnostics, and tissue engineering. PLGA is noted as FDA- and EMA-approved due to its biocompatibility, biodegradability, and mechanical properties. The review reports that PLGA-based drug delivery systems can improve drug bioavailability, reduce adverse effects, and reduce dosing frequency. However, limitations include low drug-loading capacity, high production costs, and challenges with large-scale production. The authors note that many studies remain at the basic research stage and lack extensive clinical trial data, underscoring the need for accelerated translational research.
